Back to top

Gilead Sciences, Inc. (GILD)

(Real Time Quote from BATS)

$72.36 USD


-0.58 (-0.80%)

Updated Aug 20, 2018 03:58 PM ET

After-Market: $72.35 -0.01 (-0.01%) 7:58 PM ET

Add to portfolio

1-Strong Buy 1        

B Value | F Growth | A Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $3

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.91%
2 Buy 18.62%
3 Hold 10.18%
4 Sell 5.63%
5 Strong Sell 2.37%
S&P 500 10.67%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer

Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.


Zacks Equity Research

Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.


John Blank

Time for Jackson Hole: Global Week Ahead

The world???s central bankers are going to be in Jackson Hole, Wyoming speaking to Jerome Powell and the rest of the Fed contingent. Mr. Powell himself will speak Friday morning.


Zacks Equity Research

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

Is (GILD) Outperforming Other Medical Stocks This Year?


Zacks Equity Research

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

Is (GILD) Outperforming Other Medical Stocks This Year?


Zacks Equity Research

Regeneron, Teva Announce Positive Data on Osteoarthritis Drug

Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.


Zacks Equity Research

Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.


Zacks Equity Research

Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study

Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.


Tracey Ryniec

Lessons from a Legendary Value Investor

Value investors are rare. Find out what it takes to be one and how to find value stocks from one of the greats.


Zacks Equity Research

Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years


Zacks Equity Research

Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit

Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.


Zacks Equity Research

Shire, Shionogi File NDA for Intuniv for Adults in Japan

Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.


Zacks Equity Research

Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.


Zacks Equity Research

Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.


Zacks Equity Research

Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.


Sanghamitra Saha

Biotech ETFs in Focus on String of Q2 Earnings Beat

Biotech ETFs draw attention post impressive Q2 results.


Zacks Equity Research

Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.


Zacks Equity Research

Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat

Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.


Zacks Equity Research

Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.


Zacks Equity Research

PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.


Zacks Equity Research

Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well

Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.


Zacks Equity Research

Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise

Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.


Zacks Equity Research

Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.


Zacks Equity Research

Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates

Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.


Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss

AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.


Zacks Equity Research

Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2

Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.


Zacks Equity Research

VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y

VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.


Zacks Equity Research

Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus

Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.


Zacks Equity Research

Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.


Zacks Equity Research

Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up

Radius' (RDUS) Q2 results are encouraging as sales of its lead osteoporosis drug, Tymlos, continue to gain traction.